All In Biotech

Drug Trial Radar · NCT02623699

An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS)

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis and Confirmed Superoxide Dismutase 1 Mutation

Last checked: Nov 20, 2026Latest source record: Jul 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

176

Actual

Start

Jan 20, 2016

Primary completion

Jul 16, 2021

Study completion Jul 16, 2021

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
Ionis Pharmaceuticals, Inc.
First posted
Dec 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of Parts A and B of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of tofersen in adults with ALS and a documented superoxide dismutase 1 (SOD1) mutation. The primary objective of Part C of this study is to evaluate the clinical efficacy of tofersen administered to adults with ALS and a confirmed SOD1 mutation. The secondary objective of Parts A and B of this study is to evaluate the effects of tofersen on levels of total SOD1 protein in the cerebrospinal fluid (CSF). The secondary objectives of Part C are to evaluate the safety, tolerability, pharmacodynamic (PD), and biomarker effects of tofersen.

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • TofersenDrug

    Administered as specified in the treatment arm.

  • PlaceboDrug

    Administered as specified in the treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Part A: First dose up to Day 63; Part B: First dose up to Day 289
  2. Parts A and B: Number of Participants With Clinically Significant Laboratory AbnormalitiesTime frame: Part A: Up to Day 57; Part B: Up to Day 169
  3. Parts A and B: Number of Participants With Clinically Significant Vital Sign AbnormalitiesTime frame: Part A: Up to Day 57; Part B: Up to Day 169
  4. Parts A and B: Number of Participants With Clinically Significant Physical Examination AbnormalitiesTime frame: Part A: Up to Day 57; Part B: Up to Day 169
  5. Parts A and B: Number of Participants With Clinically Significant Neurological Examination AbnormalitiesTime frame: Part A: Up to Day 57; Part B: Up to Day 169
  6. Parts A and B: Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) AbnormalitiesTime frame: Part A: Up to Day 57; Part B: Up to Day 169
  7. Parts A and B: PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax)Time frame: Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85
  8. Parts A and B: PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax)Time frame: Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85
  9. Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h)Time frame: Parts A and B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1
  10. Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
  11. Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast)Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
  12. Parts A and B: PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2)Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
  13. Parts A and B: PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2)Time frame: Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169
  14. Part C: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28Time frame: Baseline, Week 28 (Day 197)

Locations

40 sites in 12 countries. Site status is shown where the registry gives one.

  • Barrow Neurological Institute

    Phoenix, Arizona

  • University of California San Diego Medical Center

    La Jolla, California

  • California Pacific Medical Center

    San Francisco, California

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • University of Miami School of Medicine

    Miami, Florida

  • Bioclinica Research

    Orlando, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Neurology Associates, P.C.

    Lincoln, Nebraska

  • Columbia University Medical Center

    New York, New York

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Providence ALS Center

    Portland, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • New Orleans Center for Clinical Research/Volunteer Research Group, an AMR Company

    Knoxville, Tennessee

  • Methodist Neurological Institute

    Houston, Texas

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • UZ Leuven

    Leuven, Belgium

  • University of Calgary - Health Sciences Centre

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • Montreal Neurological Institute

    Montreal, Quebec, Canada

  • Bispebjerg Hospital

    Copenhagen, Denmark

  • Hopital Pitie Salpetriere

    Paris, France

  • University of Ulm

    Ulm, Baden-Wurttemberg, Germany

  • ALS Center - Dept. of Neuroscience "Rita Levi Montalcini", University of Turin

    Torino, Italy

  • The University of Tokyo Hospital

    Bunkyō City, Japan

  • Research Site

    Fukuoka, Japan

  • Research Site

    Kagoshima, Japan

  • Research Site

    Shinjuku-ku, Japan

  • Research Site

    Suita-Shi, Japan

  • Research Site

    Warsaw, Poland

  • Research Site

    Seoul, South Korea

  • Research Site

    Yangsan, Gyeongsangnam-do, South Korea

  • Research Site

    London, Greater London, United Kingdom

  • Research Site

    Sheffield, South Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.